ATXS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATXS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Astria Therapeutics has the Growth Rank of 0.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.
GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
Thank you for viewing the detailed overview of Astria Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher Morabito | officer: Chief Medical Officer | C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Perceptive Life Sciences Master Fund Ltd | director, 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Andrea Matthews | officer: Chief Business Officer | C/O ASTRIA THERAPEUTICS, INC., 75 STATE STREET, SUITE 1400, BOSTON MA 02109 |
Andrew Komjathy | officer: Chief Commercial Officer | CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B14202, CAMBRIDGE MA 02139 |
Andrew John Nichols | officer: Chief Scientific Officer | C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG 1400E, CAMBRIDGE MA 02139 |
Perceptive Xontogeny Venture Fund, Lp | director, 10 percent owner | C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Jonathan Violin | director | 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087 |
Fred Callori | director | 100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110 |
Xontogeny, Llc | director, 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Perceptive Advisors Llc | director, 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | director, 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joanne T. Beck | director | C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ, BLD. 1400E, SUITE B14202, CAMBRIDGE MA 02139 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Hugh M Cole | director | C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Benjamin Harshbarger | officer: Secretary and General Counsel | ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
From GuruFocus
By Business Wire • 10-16-2024
By GuruFocus News • 02-12-2025
By Business Wire • 02-04-2025
By Business Wire • 10-02-2024
By Business Wire • 11-04-2024
By Business Wire • 03-04-2025
By Business Wire • 12-10-2024
By Business Wire • 02-20-2025
By Business Wire • 01-03-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.